此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ACP-211单药治疗抗抑郁药反应不足的重度抑郁症 (NORLIGHT)

2026年11月3日 更新者:ACADIA Pharmaceuticals Inc.

一项关于ACP-211单药治疗在成人重度抑郁症及抗抑郁治疗应答不足患者中的双盲、安慰剂对照、平行分组、疗效与安全性研究

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).

The main questions the study aims to answer are:

  • Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression?
  • What adverse events do participants have when taking ACP-211?

研究概览

研究类型

介入性

注册 (估计的)

153

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35294
        • 撤销
        • University of Alabama at Birmingham
    • California
      • Chino、California、美国、91710
        • 招聘中
        • Inland Psychiatric Medical Group
      • Glendale、California、美国、91107
        • 招聘中
        • Behavioral Research Specialists, LLC
      • La Jolla、California、美国、92037
        • 招聘中
        • Kadima Neuropsychiatry Institute
      • Orange、California、美国、92866
        • 招聘中
        • PNS Clinical Research LLC dba ATP Clinical Research
      • West Hills、California、美国、91307
        • 招聘中
        • Focus Clinical Research, LLC d/b/a Alliance Clinical West Hills
    • Colorado
      • Denver、Colorado、美国、80209
        • 招聘中
        • Mountain View Clinical Research
    • Florida
      • Fort Myers、Florida、美国、33901
        • 招聘中
        • New Access Research and Medical Services, Inc.
      • Hollywood、Florida、美国、33021
        • 招聘中
        • The Medici Medical Research
      • Largo、Florida、美国、33777
        • 撤销
        • Sandhill Research, LLC/DBA Accel Research Sites
      • Orlando、Florida、美国、32801
        • 招聘中
        • Clinical Neuroscience Solutions, Inc.
      • Tampa、Florida、美国、33629
        • 招聘中
        • IPTB Clinical Research
      • West Palm Beach、Florida、美国、33407
        • 招聘中
        • Neuroscience Research Institute, Inc.
    • Massachusetts
      • Watertown、Massachusetts、美国、02472
        • 招聘中
        • Adams Clinical, Inc.
      • Worcester、Massachusetts、美国、01608
        • 招聘中
        • Vitalix Clinical, Inc.
    • Mississippi
      • Flowood、Mississippi、美国、39232
        • 招聘中
        • Precise Research Centers
    • Missouri
      • Saint Charles、Missouri、美国、63304
        • 招聘中
        • St. Charles Psychiatric Associates, Inc. dba Midwest Research Group
    • Nebraska
      • Lincoln、Nebraska、美国、68526
        • 招聘中
        • Alivation Research, LLC
    • Nevada
      • Las Vegas、Nevada、美国、89134
        • 招聘中
        • Redbird Research LLC
    • New Jersey
      • Marlton、New Jersey、美国、08053
        • 撤销
        • CenExel Hassman Research Institute, LLC
    • New York
      • Brooklyn、New York、美国、11229
        • 招聘中
        • Integrative Clinical Trials LLC
    • North Carolina
      • Cary、North Carolina、美国、27511
        • 招聘中
        • Magnolia Clinical Research, LLC
    • Ohio
      • North Canton、Ohio、美国、44720
        • 招聘中
        • Neuro-Behavioral Clinical Research
    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • Baylor College of Medicine
      • Houston、Texas、美国、77081
        • 撤销
        • Dynamed Clinical Research LP d/b/a DM Clinical Research
      • Katy、Texas、美国、77450
        • 招聘中
        • Olympus Clinical Research, LLC
      • The Woodlands、Texas、美国、77381
        • 招聘中
        • Family Psychiatry of The Woodlands
    • Utah
      • Salt Lake City、Utah、美国、84105
        • 招聘中
        • Aura Wellness

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults ≥18 and ≤65 years of age
  • Provides written informed consent
  • Clinical diagnosis of MDD
  • History of inadequate response to at least two antidepressants, with at least one inadequate response documented during the current episode
  • Currently treated with an approved antidepressant at a stable dose prior to Screening
  • MADRS total score ≥28, CGI-S score ≥4, and QIDS-SR16 score ≥14 at Screening and Baseline
  • Females of childbearing potential must have a negative pregnancy test and agree to use acceptable contraception; males must agree to use barrier protection and refrain from sperm donation

Exclusion Criteria:

  • Current diagnosis of certain personality disorders or persistent depressive disorder
  • Recent substance use disorders, excluding caffeine or nicotine
  • Active suicidal risk or recent suicidal attempt
  • History of schizophrenia, psychotic disorders, bipolar disorder, or MDD with psychotic features
  • Current treatment requirement for PTSD, acute stress disorder, panic disorder, or OCD
  • History of neuroleptic malignant syndrome, serotonin syndrome, or epilepsy (except single febrile seizure in infancy)
  • Allergy or sensitivity to ketamine or esketamine
  • Significant cardiovascular disease
  • Positive history of hepatitis B, hepatitis C, or HIV infection
  • Unstable diabetes or uncontrolled medical conditions
  • Positive urine drug test for an illicit drug or cannabis
  • Received neuromodulation therapies (ECT, TMS, VNS, DBS) in the current depressive episode
  • Recent initiation or change in psychotherapy

Additional inclusion/exclusion criteria apply. Participants will be evaluated at Screening to ensure that all criteria for study participation are met.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:ACP-211 600 mg

ACP-211 600 mg, administered orally twice weekly

ACP-211 monotherapy

实验性的:ACP-211 300 mg

ACP-211 300 mg, administered orally twice weekly

ACP-211 monotherapy

安慰剂比较:Placebo

Matching placebo, administered orally twice weekly

Placebo control

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Day 28
大体时间:Baseline and Day 28

The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. It consists of 10 items, each scored from 0 (no symptoms) to 6 (severe symptoms), resulting in a total score range of 0 to 60. Higher scores indicate greater depression severity.

Baseline and Day 28

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in MADRS Total Score at Scheduled Postbaseline Visits
大体时间:Baseline through Day 28
Baseline through Day 28
Proportion of Subjects in Remission at Scheduled Postbaseline Visits (MADRS ≤10)
大体时间:Up to Day 28
Up to Day 28
Proportion of Subjects With Response at Scheduled Postbaseline Visits (≥50% Reduction From Baseline in MADRS Total Score)
大体时间:Up to Day 28
Up to Day 28
Change From Baseline in MADRS Total Score at Day 2
大体时间:Baseline and Day 2 (24 hours postdose)

The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. It consists of 10 items, each scored from 0 (no symptoms) to 6 (severe symptoms), resulting in a total score range of 0 to 60. Higher scores indicate greater depression severity.

Baseline and Day 2 (24 hours postdose)
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Scheduled Postbaseline Visits
大体时间:Baseline through Day 28

The CGI-S is a clinician-rated assessment of illness severity scored on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicate greater illness severity.

Baseline through Day 28
Proportion of Subjects With Sustained Response From Day 2 Through Day 28
大体时间:Day 2 through Day 28

Subjects achieving sustained response, defined as a ≥50% reduction from Baseline in MADRS total score, with onset by Day 2 and maintained through the end of the double-blind treatment period.

Day 2 through Day 28
Proportion of Subjects With Clinical Global Impression of Improvement (CGI-I) Score of 1 or 2 at Scheduled Postbaseline Visits
大体时间:Up to Day 28

The CGI-I is a clinician-rated assessment of change in illness relative to Baseline. Scores range from 1 (very much improved) to 7 (very much worse). This outcome evaluates subjects with a score of 1 (very much improved) or 2 (much improved).

Up to Day 28

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月14日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2025年12月9日

首先提交符合 QC 标准的

2025年12月9日

首次发布 (实际的)

2025年12月16日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅